InsidersTradesSigma
Total declarations
Companies
▲ Purchases (2 ops.)
▼ Sales (0 ops.)
Explore the full record of transactions filed by WEAVER GREGORY L, Chief Financial Officer. Insider active across 2 companies, notably ATAI Life Sciences N.V.. Aggregated, 4 disclosures have been logged. Total volume traded: €117k. The latest transaction was filed on 2 July 2021 — Levée d'options. Regulator: SEC (Form 4). All data is openly available.
Declarations4 total
€21,8104,581 shares@ €4.7610.052% mcap100.0% of flow
Common Stock
SEC:0001437749-21-016573·
€21,8104,581 shares@ €4.7610.052% mcap50.0% of flow
Common Stock
SEC:0001437749-21-016573:0·
€58,6344,666 shares@ €12.5663100.0% of flow
Common Shares
SEC:0000899243-21-025732·
Ideal exit: 19 Mar 2022 (T+270)
€58,6344,666 shares@ €12.56630.0039% mcap50.0% of flow
Common Shares
SEC:0000899243-21-025732:0·
Ideal exit: 19 Mar 2022 (T+270)
4 of 4 declarations
About WEAVER GREGORY L
Gregory L. Weaver is the Chief Financial Officer and Board Member at ATAI Life Sciences N.V. and Atossa Therapeutics, Inc. He is responsible for financial management, strategic planning, and performance analysis. His role is essential in ensuring the financial health of the companies and supporting their long-term growth.
